Astrazeneca PLC (AZN) Given Average Recommendation of “Hold” by Brokerages
Shares of Astrazeneca PLC (NYSE:AZN) have been given a consensus rating of “Hold” by the twenty-eight analysts that are currently covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and twelve have issued a buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $33.68.
Several equities analysts have issued reports on AZN shares. Goldman Sachs Group, Inc. (The) reiterated a “sell” rating on shares of Astrazeneca PLC in a research report on Thursday, July 13th. Barclays PLC reiterated an “overweight” rating on shares of Astrazeneca PLC in a research report on Thursday, July 13th. Leerink Swann downgraded Astrazeneca PLC from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $36.00 to $31.00 in a research report on Thursday, July 27th. Zacks Investment Research downgraded Astrazeneca PLC from a “strong-buy” rating to a “sell” rating in a research report on Monday, July 17th. Finally, BMO Capital Markets started coverage on Astrazeneca PLC in a research report on Wednesday, September 6th. They issued an “outperform” rating and a $38.00 price objective for the company.
Institutional investors have recently made changes to their positions in the stock. Meeder Asset Management Inc. acquired a new stake in shares of Astrazeneca PLC during the second quarter worth $105,000. Salem Investment Counselors Inc. acquired a new stake in shares of Astrazeneca PLC during the first quarter worth $107,000. Tower Research Capital LLC TRC grew its stake in shares of Astrazeneca PLC by 3,782.0% during the first quarter. Tower Research Capital LLC TRC now owns 3,882 shares of the company’s stock worth $121,000 after purchasing an additional 3,782 shares during the period. WFG Advisors LP grew its stake in shares of Astrazeneca PLC by 36.0% during the second quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock worth $127,000 after purchasing an additional 984 shares during the period. Finally, Parallel Advisors LLC grew its stake in shares of Astrazeneca PLC by 27.1% during the first quarter. Parallel Advisors LLC now owns 4,526 shares of the company’s stock worth $138,000 after purchasing an additional 964 shares during the period. 14.18% of the stock is owned by institutional investors and hedge funds.
Astrazeneca PLC (NYSE AZN) traded down 0.28% on Friday, hitting $32.53. The stock had a trading volume of 3,100,668 shares. The firm has a market cap of $82.37 billion, a P/E ratio of 21.34 and a beta of 0.74. Astrazeneca PLC has a 1-year low of $25.55 and a 1-year high of $35.60. The firm’s 50-day moving average price is $30.20 and its 200-day moving average price is $31.74.
Astrazeneca PLC (NYSE:AZN) last issued its quarterly earnings data on Thursday, July 27th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.46. Astrazeneca PLC had a return on equity of 35.90% and a net margin of 17.80%. The firm had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $5.04 billion. During the same quarter in the previous year, the company posted $0.83 EPS. The business’s revenue for the quarter was down 9.9% compared to the same quarter last year. On average, equities research analysts predict that Astrazeneca PLC will post $1.90 earnings per share for the current year.
The business also recently disclosed a None dividend, which was paid on Monday, September 11th. Investors of record on Friday, August 11th were paid a dividend of $0.44 per share. The ex-dividend date of this dividend was Wednesday, August 9th. This represents a dividend yield of 2.98%. Astrazeneca PLC’s dividend payout ratio (DPR) is presently 44.92%.
TRADEMARK VIOLATION WARNING: “Astrazeneca PLC (AZN) Given Average Recommendation of “Hold” by Brokerages” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/16/astrazeneca-plc-azn-given-average-recommendation-of-hold-by-brokerages.html.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.